UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted
AstraZeneca acquires bioconjugation biotech Omniose
Omniose, a preclinical biotechnology company based in St. Louis, is now a wholly owned subsidiary of AstraZeneca within its Infectious Disease Unit. The deal brings Omniose's proprietary bioconjugation platform into AstraZeneca following a three-year exclusive research collaboration. Terms were not disclosed.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →